Clinical trial
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or…
NCT00005962 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00005962 |
|---|---|
| Title | Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia |
| Official title | A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | sargramostim, cyclophosphamide, cytarabine, gemtuzumab ozogamicin, liposomal daunorubicin citrate, topotecan hydrochloride |
| Start date | Oct 4, 2000 |
| Primary completion | Oct 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Nov 5, 2003 |
| Last update posted | Jun 22, 2023 |
| Countries | Puerto Rico, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: